Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + low-dose amoxicillin 7-day dual therapy vs PPI-based bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2100054067Phase 4Recruiting
- Sponsor
- Qingyuan People's Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan and omeprazole in Helicobacter pylori infection (2 arms), sponsored by Qingyuan People's Hospital. Primary endpoint: Helicobacter pylori eradication rate. Started Aug 2022; status: recruiting.
02
Drugs
vonoprazanomeprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100054067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054067.